2-Aryl-1<i>H</i>-imidazo[4,5-<i>f</i>][1,10]phenanthroline-Based Binuclear Ru(II)/Ir(III)/Re(I) Complexes as Mitochondria Targeting Cancer Stem Cell Therapeutic Agents-Reference-Cited by-同舟云学术

2-Aryl-1H-imidazo[4,5-f][1,10]phenanthroline-Based Binuclear Ru(II)/Ir(III)/Re(I) Complexes as Mitochondria Targeting Cancer Stem Cell Therapeutic Agents

Published:2024-05-30 Issue:13 Volume:67 Page:10928-10945
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Kar Binoy¹^ORCID,Shanavas Shanooja²,Karmakar Arun³^ORCID,Nagendra Apoorva H.²,Vardhan Seshu⁴^ORCID,Sahoo Suban K⁴^ORCID,Bose Bipasha²,Kundu Subrata³^ORCID,Paira Priyankar¹^ORCID

Affiliation:

1. Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, Tamil Nadu 632014, India

2. Department Stem Cells and Regenerative Medicine Centre, Institution Yenepoya Research Centre, Yenepoya University, University Road, Derlakatte, Mangalore, 575018 Karnataka, India

3. Materials Chemistry Laboratory for Energy, Environment and Catalysis, Electrochemical Process Engineering (EPE) Division, CSIR-Central Electrochemical Research Institute (CECRI), Karaikudi, Tamil Nadu 630003, India

4. Department of Applied Chemistry, S. V. National Institute of Technology (SVNIT), Ichchanath Surat, Gujarat 395007, India

Funder

Science and Engineering Research Board

VIT University

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00406

Reference61 articles.

1. Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?

2. A hydrolytically stable oxo-rhenium(v) antitumor agent for synergistic combination therapy with cisplatin: from synthesis and mechanistic studies to toxicity assessment in zebrafish

3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

4. The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

5. Cisplatin in cancer therapy: Molecular mechanisms of action